Vera Therapeutics (VERA) Non Operating Investment Income (2021 - 2024)
Vera Therapeutics (VERA) posted Non Operating Investment Income of -$7000.0 for Q2 2024, down 75.0% on a QoQ basis from -$4000.0 in Q1 2024, and up 75.0% year-over-year from -$4000.0 in Q3 2023.
Vera Therapeutics (VERA) Non Operating Investment Income (2021 - 2024) Analysis & Trends
Vera Therapeutics' Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$7000.0 for Q2 2024.
- Quarterly Non Operating Investment Income rose 75.0% year-over-year to -$7000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$28000.0 (up 90.51% YoY) and the FY2023 annual result came in at -$47000.0, up 94.19% from the prior year.
- Non Operating Investment Income was -$7000.0 for Q2 2024 at Vera Therapeutics, down from -$4000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at -$1000.0 in Q1 2023 and bottomed at -$364000.0 in Q3 2021.
- A 4-year average of -$135230.8 and a median of -$64000.0 in 2022 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income soared 99.65% — and 2024, when it plunged 300.0%.
- Vera Therapeutics' Non Operating Investment Income stood at -$247000.0 in 2021, then jumped by 74.09% to -$64000.0 in 2022, then soared by 96.88% to -$2000.0 in 2023, then sank by 250.0% to -$7000.0 in 2024.
- Business Quant data shows VERA's Non Operating Investment Income at -$7000.0 in Q2 2024, -$4000.0 in Q1 2024, and -$2000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | Vera Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -28,000.00 |
| Jun 30, 2023 | -28,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -64,000.00 |
| Dec 31, 2022 | -64,000.00 |
| Sep 30, 2022 | -202,000.00 |
| Sep 30, 2022 | -202,000.00 |
| Jun 30, 2022 | -256,000.00 |
| Jun 30, 2022 | -256,000.00 |
| Mar 31, 2022 | -287,000.00 |
| Mar 31, 2022 | -287,000.00 |